Pharmaceuticals
Rebecca Beausang
May 26, 2026
Most people assume that because a drug is still investigational, the manufacturing requirements are less stringent. That assumption is incorrect, and it’s a costly one to act on. In reality, manufacturing an Investigational Medicinal Product (IMP), the term used under EU/UK GMP; in the US, the equivalent falls under an Investigational New Drug (IND) application, is often more complex than commercial production. Batches are small, formulations change frequently, and blinding requirements add a layer of risk that commercial manufacturing doesn’t face. Without proper clinical trial GMP training, a single labeling error can unblind a study and put months of research and significant investment at risk.
Regulatory bodies including the FDA and EMA are explicit on this point: a Phase 1 investigational drug is expected to meet the same fundamental quality standards as an approved, commercially available medicine. The rationale is straightforward, these products are administered to human volunteers, and manufacturers carry both a legal and ethical obligation to ensure they are pure, stable, and consistent with what the protocol specifies. In the EU, this is set out in Annex 13 to the EU GMP Guide (Manufacture of Investigational Medicinal Products); in the US, IND products fall under 21 CFR Part 211, with FDA guidance allowing a phase-appropriate approach to GMP during early development. A team without training in these specific requirements risks more than a failed audit, it risks the safety of trial participants.
One of the biggest hurdles in clinical manufacturing is that the process is not yet fully validated. In commercial GMP, years of data confirm a process performs consistently; in clinical manufacturing, the process itself may still be evolving. Manufacturing methods can change between Phase 2 and Phase 3, and each shift requires rigorous documentation and oversight. Rather than relying on a static process, teams need a robust Quality Risk Management (QRM) system to identify where scale-up or a change in container closure system could introduce risk.
GMP for IMP training addresses exactly this gap. It teaches teams how to manage quality in a changing environment and how to document those changes so that, when the drug eventually moves toward an NDA, MAA, or other marketing application, regulators can see a clear, compliant history of how the product evolved. Regulatory submissions are sometimes delayed for months when a sponsor cannot adequately explain a shift in impurity profile between clinical batches — a gap in oversight that proper training is designed to catch early.
Labeling is consistently cited by clinical supply managers as one of the highest-risk steps in the process. In a double-blind study, active drug and placebo must be visually indistinguishable — identical weight, color, size, and packaging. Even a minor inconsistency can allow an investigator or patient to identify treatment assignment. Unplanned or premature unblinding can compromise study data; depending on scope and timing, this can range from a documented protocol deviation to a much larger integrity issue that jeopardizes the trial’s results.
Clinical trial GMP training addresses packaging and labeling operations in depth, including the coding systems used to track patient-to-product assignment and the double-check procedures required during labeling runs. A single mislabeled unit can have consequences well beyond the cost of the product itself. Certifying staff in these specific clinical requirements builds a meaningful safeguard around trial data integrity.
To address these unique challenges, GxP-Training offers a specialized certification program. This clinical trial GMP training course is designed for professionals who need to bridge the gap between traditional manufacturing and the specific needs of clinical research. It provides a synthesis of global regulations and practical floor-level strategies.
Course Details
This material was built by a team of Regulatory Affairs Experts and is delivered by senior instructors who connect the theory of clinical trial GMP with day-to-day practice.
Detailed Curriculum Overview
A common mistake is training only the production staff. In a clinical trial, however, the supply chain includes many different players, and a gap anywhere in that chain creates risk. If the person responsible for shipping the drug doesn’t understand GMP requirements, a box left on a hot loading dock could compromise the stability of an entire batch. Everyone who touches the product needs a shared understanding of the requirements.
Specifically, these roles should prioritize clinical trial GMP training:
Training the full team removes the silos that lead to communication breakdowns between manufacturing and clinical operations. When everyone understands that the shared goal is a safe, compliant product, the site itself becomes a benchmark for regulatory excellence.
Clinical GMP responsibilities do not end once the drug is in its container. Shipping clinical supplies is inherently complex — small quantities of product are often sent to dozens of countries, each with its own import requirements, while temperature, location, and delivery timing must all be tracked and maintained. This is why Clinical Trial Quality Assurance training also needs to cover Good Distribution Practice (GDP).
Sponsors must also plan for the end of the study. Unused drug cannot simply be discarded; a documented process for returns and destruction is required, and regulators expect a full accounting of every unit produced. If 10,000 tablets were manufactured, the fate of every one needs to be traceable — an inability to account for even 50 tablets signals a failure in inventory control. This level of traceability is a core focus of GMP for IMP training.
Some organizations take the position that rigorous GMP can wait until Phase 3. In practice, this is a costly approach. If Phase 1 or Phase 2 manufacturing data is incomplete or poorly documented, regulators may not permit the program to advance, and sponsors can find themselves repeating studies because they cannot demonstrate that the drug used in Phase 1 was equivalent to the drug used in Phase 2.
Investing in clinical GMP early reduces the risk of batch failures, helps prevent unblinding incidents, and allows regulatory filings to move through review more smoothly. It also builds investor confidence: a professional, inspection-ready operation signals that a company can withstand FDA or EMA scrutiny at any stage. Heading into 2026, where delays carry a direct and growing cost, a strong quality system remains one of a clinical program’s most important assets.
Clinical teams are under significant pressure to meet deadlines, and time spent on generic coursework that doesn’t translate to daily practice is time few teams can afford. GxP-Training’s courses are built around actionable, applicable knowledge.
Manufacturing investigational drugs leaves little margin for error. A single misstep can have significant consequences for both a company and the patients it serves. Certifying a team in clinical trial GMP training provides more than technical knowledge; it builds a culture of quality that goes beyond compliance for its own sake, creating a team that understands the science behind participant safety.
